King begins hostile takeover proceedings with Alpharma - Brain Markison, King’s ceo, is disappointed that Dean Mitchell, Alpharma’s ceo, hasn’t responded to his initial offer $1.4 billion offer, which …
August ’08 Pharma News
The Xa factor: not looking so promising for Pfizer and Bristol - Bristol-Myers Squibb and Pfizer's apixaban blood clot preventer raised rates of bleeding in a 6-month study but showed some encouraging …